Park Place Capital’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$233K Buy
+3,984
New +$235K 0.09% 178
2026
Q2
– Sell
-3,485
Closed -$167K – 688
2026
Q1
$167K Hold
3,485
– – 0.03% 205
2025
Q4
$135K Hold
3,485
– – 0.03% 220
2025
Q3
$123K Hold
3,485
– – 0.03% 230
2025
Q2
$125K Hold
3,485
– – 0.03% 247
2025
Q1
$108K Buy
+3,485
New +$110K 0.03% 248
2024
Q4
– Sell
-3,753
Closed -$106K – 866
2024
Q3
$106K Sell
3,753
-65
-2% -$1.8K 0.03% 281
2024
Q2
$101K Sell
3,818
-1,250
-25% -$34.6K 0.03% 275
2024
Q1
$154K Sell
5,068
-588
-10% -$17.3K 0.06% 264
2023
Q4
$159K Buy
5,656
+1,939
+52% +$53.3K 0.06% 248
2023
Q3
$101K Hold
3,717
– – 0.03% 342
2023
Q2
$114K Hold
3,717
– – 0.03% 324
2023
Q1
$134K Sell
3,717
-72
-2% -$2.67K 0.04% 299
2022
Q4
$150K Buy
+3,789
New +$158K 0.04% 281

Other funds holding RPRX

Park Place Capital's RPRX Position: Q3 2026 in Review

Park Place Capital opened a new position in Royalty Pharma (RPRX) in Q3 2026: 3,984 shares worth $233K. The stake represents 0.09% of the portfolio and ranks #178 among its holdings. This is a return to the name: Park Place Capital previously reported a position in RPRX as recently as Q1 2026.

Park Place Capital first reported a position in RPRX in Q4 2022 and has held it in 14 quarters since. 705 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Park Place Capital held 3,984 shares of Royalty Pharma worth $233K as of Q3 2026.
  • Royalty Pharma was a new Park Place Capital position in Q3 2026.
  • Royalty Pharma made up 0.09% of Park Place Capital's portfolio in Q3 2026, its #178 holding.
  • Park Place Capital first reported a position in Royalty Pharma in Q4 2022 and has held it in 14 quarters since.
  • 705 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Park Place Capital's 13F filing for Q3 2026, filed 9 Nov 2026.